These data provide support for the application of NX-2127’s unique combination of BTK degradation and IMiD activity as a therapy for B-cell malignancies with potentially enhanced efficacy over the individual therapy classes alone. In a poster presentation entitled: Concurrent degradation of BTK and IMiD neosubstrates by NX-2127 enhances multiple mechanisms of tumor killing (Abstract 1126), Nurix scientists present data that demonstrate the bifunctional activity of NX-2127 to degrade Bruton’s tyrosine kinase (BTK) and immunomodulatory imide drug (IMiD) neosubstrates, Aiolos and Ikaros.
We plan to provide clinical updates from both programs in the second half of 2022.” “These presentations showing the unique activity of two proprietary small molecule protein modulators, NX-2127 and NX-0255, provide clear scientific rationale supporting our ongoing clinical programs for NX-2127 in B-cell malignancies and DeTIL-0255 for solid tumors. Hansen, Ph.D., Nurix’s chief scientific officer. “Our data presentations at the AACR meeting highlight the breadth and potential of our protein modulation platform to create therapies that could be transformative for patients with cancer,” said Gwenn M. The meeting is being held from April 8-13, 2022 in New Orleans, LA. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of preclinical data that support the clinical development of investigative therapies NX-2127 and DeTIL-0255, for the treatment of B-cell malignancies and solid tumors, respectively, at the American Association for Cancer Research (AACR) Annual Meeting. SAN FRANCISCO, CA, USA I ApI Nurix Therapeutics, Inc.
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killingĪnimal models of adoptive cell therapy support the use of NX-0255 in the production of an investigational drug-enhanced TIL therapy, DeTIL-0255